A letter to sherholders for IR-MED. Hopefully th
Post# of 86949
(Total Views: 521)
Posted On: 08/24/2023 11:17:28 AM
A letter to sherholders for IR-MED.
Hopefully this relationship will pay future dividends to UNVC shareholders:
IR-MED Chairman & Interim CEO Issues Letter to Shareholders
9:15 am ET August 21, 2023 (Globe Newswire) Print
GlobeNewswireAugust 21, 2023
Rosh Pina, Israel, Aug. 21, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., ("IR-MED" or the "Company"
(OTCQB:IRME), developer of a noninvasive AI-driven infrared spectrographic analysis technology platform to address significant healthcare needs, today issued the following update to shareholders from its Chairman & Interim Chief Executive Officer.
Dear Shareholders,
On behalf of the Board and entire the team at IR MED, we thank you for being a long term shareholder of our company. Your trust in our ability to execute on a multi-billion opportunity is appreciated and it is our hope that you will be well-rewarded.
As you may well be aware, we plan to uplist our common stock to a major exchange in the U.S., perhaps the Nasdaq or NYSE. We recently published our company's presentation which provides further detail on our technology, product pipeline, and markets. It can be found: HERE.
Important developments currently underway that are highlighted in the presentation include:
We plan to list PressureSafe(TM) with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2023, and pending regulatory approval, we expect commercial launch in the U.S. in the first half of 2024.
PressureSafe addresses a $600 million market opportunity1 in the U.S. and $2.9 billion globally2.
A distributor in the U.S. is already in place and ready to launch in the first half of 2024, pending regulatory approval. The distributor will target hospitals, nursing homes, long term care facilities, and at-home care.
The latest interim clinical data showed that PressureSafe identifies early-stage pressure injuries with 96% accuracy.
In addition to the U.S., we plan to file for regulatory approval and launch PressureSafe in other markets including Canada and Europe.
We are building a portfolio of products that address other significant markets where patients and healthcare payors can reap the benefits of our platform technology.
We invite you to follow our news closely as we launch PressureSafe to change the treatment paradigm for pressure injuries through early detection.
Sincerely,
Oded Bashan
Executive Chairman of the Board & Interim CEO
IR-MED. Inc
Hopefully this relationship will pay future dividends to UNVC shareholders:
IR-MED Chairman & Interim CEO Issues Letter to Shareholders
9:15 am ET August 21, 2023 (Globe Newswire) Print
GlobeNewswireAugust 21, 2023
Rosh Pina, Israel, Aug. 21, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., ("IR-MED" or the "Company"
(OTCQB:IRME), developer of a noninvasive AI-driven infrared spectrographic analysis technology platform to address significant healthcare needs, today issued the following update to shareholders from its Chairman & Interim Chief Executive Officer. Dear Shareholders,
On behalf of the Board and entire the team at IR MED, we thank you for being a long term shareholder of our company. Your trust in our ability to execute on a multi-billion opportunity is appreciated and it is our hope that you will be well-rewarded.
As you may well be aware, we plan to uplist our common stock to a major exchange in the U.S., perhaps the Nasdaq or NYSE. We recently published our company's presentation which provides further detail on our technology, product pipeline, and markets. It can be found: HERE.
Important developments currently underway that are highlighted in the presentation include:
We plan to list PressureSafe(TM) with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2023, and pending regulatory approval, we expect commercial launch in the U.S. in the first half of 2024.
PressureSafe addresses a $600 million market opportunity1 in the U.S. and $2.9 billion globally2.
A distributor in the U.S. is already in place and ready to launch in the first half of 2024, pending regulatory approval. The distributor will target hospitals, nursing homes, long term care facilities, and at-home care.
The latest interim clinical data showed that PressureSafe identifies early-stage pressure injuries with 96% accuracy.
In addition to the U.S., we plan to file for regulatory approval and launch PressureSafe in other markets including Canada and Europe.
We are building a portfolio of products that address other significant markets where patients and healthcare payors can reap the benefits of our platform technology.
We invite you to follow our news closely as we launch PressureSafe to change the treatment paradigm for pressure injuries through early detection.
Sincerely,
Oded Bashan
Executive Chairman of the Board & Interim CEO
IR-MED. Inc
(10)
(2)